TI-2007-06454 Aliases CVE-2007-6763 GHSA-9v4f-qv93-x5wc

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user…

MEDIUM 41CWE-20Published 2019-07-31 · Updated 2024-08-07

Key facts

Attack vector: Network
Privileges required: Low
User interaction: None
Attack complexity: Low
Impact type: —
Confidentiality · integrity · availability: High · High · High
Fix status: No fix listed

Attack profile from CVSS 3.0 · NVD. Fix status from CNA.

Summary

SAS Drug Development (SDD) before 32DRG02 mishandles logout actions, which allows a user (who was previously logged in) to access resources by pressing a back or forward button in a web browser.

Why it matters now

EPSS 0.0132 71st percentileScored 2026-11-07

Fix No fix listed No fixed version in the sources yet

SSVC decision points

Not available: CISA has not published SSVC decision points for this record.

Affected products

Vendor	Product	Affected versions	Fixed in	Status	Source
—	—	all versions	—	No fix listed	CNA

— Vendor— Affected all versions Fixed in — No fix listed CNA

CPE configurations NVD · 1

CPE	Versions	Role	Vendor
cpe:2.3:a:sas:sas_drug_development::::::::	before 32drg02	Vulnerable	Sas

cpe:2.3:a:sas:sas_drug_development:*:*:*:*:*:*:*:* Versions before 32drg02 Vulnerable ·Sas

Remediation

No fixed version listed by the sources yet.

Timeline

2026-10-02 Threatist record created from CVE-2007-6763
2026-10-03 Alias added: GHSA-9v4f-qv93-x5wc

References

Advisory 1

http://ftp.sas.com/techsup/download/hotfix/drugdev/32drg02/SDD_Release_Notes_32DRG02.pdf

Sources

This product uses the NVD API but is not endorsed or certified by the NVD. Sources and licences